|
To: [HCP email]
From: NeurologyLive <news@neurologylive.com>
Subject: The Science of VYEPTI™ (eptinezumab-jjmr)
No Images? Click here
|
|
|
|
|
The Science of Monoclonal
Antibodies and the Emergence of
VYEPTI™ (eptinezumab-jjmr) for the
Preventive Treatment of Migraine
This iPub® is sponsored by Lundbeck and is not
approved for Continuing Medical Education.
|
|
|
|
|
Join our expert faculty to learn more about VYEPTI for the preventive treatment of migraine in adults. VYEPTI is the first and only intravenous calcitonin gene-related peptide antagonist (IV anti-CGRP) specifically designed to deliver fast, powerful, and sustained migraine prevention.1,2
|
|
|
|
|
Jessica Ailani, MD, FAHS, FAAN
Professor of Clinical Neurology
Director, Georgetown Headache Center
MedStar Georgetown University Hospital
Washington, DC
|
|
|
|
Andrew Charles, MD
Professor of Neurology
Meyer and Renee Luskin Chair
in Migraine and Headache Studies
Director, Goldberg Migraine Program
David Geffen School of Medicine
University of California, Los Angeles
Los Angeles, CA
|
|
|
|
|
|
In this iPub®, Drs. Jessica Ailani and Andrew Charles will:
|
|
|
|
|
Review migraine pathophysiology, the role of CGRP, and the rationale for CGRP as a therapeutic target in migraine prevention
|
|
|
|
|
|
|
Provide perspectives on the science behind therapeutic monoclonal antibodies, with a focus on specific design elements
|
|
|
|
|
|
|
Evaluate the pharmacokinetics and potential mechanism of action of eptinezumab-jjmr
|
|
|
|
|
|
|
Explore the efficacy and safety profile of
VYEPTI™ (eptinezumab-jjmr) and examine considerations for appropriate patients
|
|
|
|
|
|
|
|
|
|
|
Indication
VYEPTI is indicated for the preventive treatment of migraine in adults.
Important Safety Information
CONTRAINDICATIONS
VYEPTI is contraindicated in patients with serious hypersensitivity to
eptinezumab-jjmr or to any of the excipients. Reactions have included
angioedema.
WARNINGS AND PRECAUTIONS
Hypersensitivity reactions: Hypersensitivity reactions, including
angioedema, urticaria, facial flushing, and rash, have occurred with
VYEPTI in clinical trials. Most hypersensitivity reactions occurred during
infusion and were not serious, but often led to discontinuation or
required treatment. Serious hypersensitivity reactions may occur. If a
hypersensitivity reaction occurs, consider discontinuing VYEPTI, and
institute appropriate therapy.
ADVERSE REACTIONS
The most common adverse reactions (≥2% and at least 2% or greater
than placebo) in the clinical trials for the preventive treatment of
migraine were nasopharyngitis and hypersensitivity.
For more information, please see the Prescribing Information
and
Patient Information.
References:
1. VYEPTI [package insert]. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
2. Data on file. Deerfield, IL: Lundbeck Seattle BioPharmaceuticals, Inc.
|
|
|
|
|
© 2020 Lundbeck. All rights reserved.
VYEPTI is a trademark of Lundbeck Seattle
BioPharmaceuticals, Inc.
EPT-B-100260
This program is intended for US healthcare
professionals only.
|
|
|
|
|
|
|
|
Neurology Live® – an MJH Life Sciences™ brand
Copyright 2020 © Intellisphere, LLC
2 Clarke Dr | Suite 100 | Cranbury, NJ | 08512
Preferences | Unsubscribe
|
Tweet
|
|
|
|
|
